Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report Authors: Fatma F. Shakarchi, Joseph A. Chacko, Joseph G. Chacko, Rangaswamy Govindarajan, Clive S. Zent, Sami H. Uwaydat Published: 2026 ABSTRACT PurposeWe demonstrate the potential role of acalabrutinib, a second-generation selective Bruton tyrosine kinase (BTK) inhibitor, as monotherapy in treating optic nerve infiltration by chronic lymphocytic leukemia (CLL).ObservationsA 68-year-old male, initially diagnosed with CLL 13 years earlier, presented with a decrease in vision and intermittent floaters for 5 days. On fundus examination, there was optic disc swelling in both eyes (OU) concerning for CLL infiltration and vitreous haze in the left eye (OS). The MRI of the brain and orbit was normal, and his infectious and uveitis workups were unremarkable. He was prescribed acalabrutinib 100 mg twice daily by mouth. Five days later, the optic disc edema OU and vitreous haze OS improved and completely subsided two months later.Conclusions and importanceEarly initiation of acalabrutinib may be sufficient therapy for CLL optic nerve infiltration. Introduction Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), a disease entity with leukemic and nodal manifestations, is the most prevalent lymphoid malignancy in the United States.1 It rarely causes central nervous system (CNS) infiltration (incidence: 0.8%−2%) 2, 3, 4, and the data on optic nerve or intraocular involvement by CLL is limited to case reports 5, 6, 7. There is no standard of care for the treatment of optic nerve CLL. Reported treatment modalities include systemic chemoimmunotherapy, intrathecal chemotherapy, intravenous (IV) immunoglobulin, corticosteroids, and irradiation 6, 7, 8, 9. In addition, ibrutinib has been used successfully to treat ocular involvement by CLL.10 We report the successful use of acalabrutinib, a second-generation covalent Bruton tyrosine kinase (BTK) inhibitor, in a patient with presumed optic nerve head involvement concerning for leukemic infiltration in CLL. Case report A 68-year-old male, with medical history significant for diabetes mellitus type 2 (DM), hyperlipidemia, and treatment-naïve CLL, diagnosed 13 years earlier under observation, and ocular history significant for pseudophakia in both eyes (OU), and epiretinal membrane in the left eye (OS), presented with blurry vision and intermittent floaters for 5 days in OS. He denied ocular pain, pressure, or flashes of light. Uncorrected visual acuity (VA) was 20/20-1 OU with normal intraocular pressure. Slit lamp examinations revealed well-centered intraocular lenses, with no cell or flare in the anterior chamber. On fundus examination, there was optic disc edema grade III OD with multiple peripapillary flame hemorrhages and grade II OS with one flame hemorrhage, and vitreous haze OU (Fig. 1A and C). Optical coherence tomography (OCT) revealed swelling of the peripapillary nerve fiber layer (NFL) in OU, rare infiltrates along the Henle fiber layer OD, and significant intraretinal and sub-foveal fluid in OS (Fig. 1B and D). Automated visual field testing showed enlargement of the blind spot in both eyes. Contrast-enhanced MRI of the brain and orbit was normal, demonstrating no acute intracranial abnormality, with normal-appearing bilateral optic nerves and orbits, and a focused uveitis workup was negative for syphilis, tuberculosis, toxoplasmosis, or sarcoidosis. Medication toxicity was also excluded upon medication review. His white blood cell count was 114.3 × 103/μL, Hemoglobin 11.3g/dL, and Platelet count 105 × 103/μ.Fig. 1Ocular findings at presentation in a patient with chronic lymphocytic leukemia (CLL)(a) Fundus photograph of the right eye (OD) shows blurred optic disc margins and peripapillary hemorrhages (arrow). (b) Optical coherence tomography (OCT) of OD demonstrating thickening of the peripapillary retinal nerve fiber layer (RNFL) consistent with optic disc swelling (arrow) and hyper-refractile material in the retina (asterix). (c) Fundus photograph of the left eye showing optic disc swelling with mild vitreous haze and optic disc hyperemia (arrow). (d) OCT of OS demonstrating RNFL thickening (arrow) and intraretinal and subfoveal fluid. Ocular findings at presentation in a patient with chronic lymphocytic leukemia (CLL) (a) Fundus photograph of the right eye (OD) shows blurred optic disc margins and peripapillary hemorrhages (arrow). (b) Optical coherence tomography (OCT) of OD demonstrating thickening of the peripapillary retinal nerve fiber layer (RNFL) consistent with optic disc swelling (arrow) and hyper-refractile material in the retina (asterix). (c) Fundus photograph of the left eye showing optic disc swelling with mild vitreous haze and optic disc hyperemia (arrow). (d) OCT of OS demonstrating RNFL thickening (arrow) and intraretinal and subfoveal fluid. He was diagnosed with presumed CLL optic nerve infiltration. Invasive procedures, including lumbar puncture, vitreous biopsy, or optic nerve sheath fenestration, were deemed not necessary and would not have changed the course of treatment. Treatment was started on acalabrutinib 100 mg orally twice per day. The rationale for treatment was that acalabrutinib is standard of care for therapy for progressive CLL,11 crosses the blood-brain barrier,12 and has equivalent efficacy but less toxicity than the prototype BTK inhibitor ibrutinib, which has been reported to be effective in the treatment of CLL in the CNS, including the optic nerve. On his follow-up visit, five days later, the optic disc edema OU and vitreous haze OU improved, and by the two-month follow-up mark, the optic disc edema and vitreous haze had completely subsided OS, with some residual edema OD. Three months after initiating acalabrutinib, his VA was at baseline (20/20-1 OU), the optic nerve head appearance improved, and the OCT showed resolution of the intraretinal infiltrates in OD and intraretinal and subretinal fluid in OS (Fig. 2A–D). The patient tolerated acalabrutinib well without reported treatment-limiting adverse effects. At 1-year follow-up, VA was 20/20 OU, with no relative afferent pupillary defect. Mild residual disc edema persisted OD, while the optic disc appeared sharp OS. No optic disc pallor was noted OU.Fig. 2Ocular findings in a patient with chronic lymphocytic leukemia (CLL) after three months of treatment with acalabrutinib for bilateral optic disc swelling.(a) Fundus photograph of the right eye showing complete resolution of optic disc swelling (arrow) with well-defined disc margins and no hemorrhages. (b) Optical coherence tomography (OCT) of the right eye with normalization of the peripapillary retinal nerve fiber layer (RNFL) thickness (arrow). (c) Fundus photograph of the left eye with resolution of optic disc swelling (arrow) and absence of vitreous haze. (d) OCT of the left eye showing normalized RNFL contour and thickness (arrow) with resolution of the intraretinal and subfoveal fluid. Ocular findings in a patient with chronic lymphocytic leukemia (CLL) after three months of treatment with acalabrutinib for bilateral optic disc swelling. (a) Fundus photograph of the right eye showing complete resolution of optic disc swelling (arrow) with well-defined disc margins and no hemorrhages. (b) Optical coherence tomography (OCT) of the right eye with normalization of the peripapillary retinal nerve fiber layer (RNFL) thickness (arrow). (c) Fundus photograph of the left eye with resolution of optic disc swelling (arrow) and absence of vitreous haze. (d) OCT of the left eye showing normalized RNFL contour and thickness (arrow) with resolution of the intraretinal and subfoveal fluid. Discussion CLL patients can present with ophthalmic or CNS infiltration, which can be the only site of disease. In addition, ophthalmic disease can be the first indication for treatment in up to two-thirds of patients with CNS involvement.13 Optic nerve involvement in leukemic patients is considered an emergency. Early diagnosis and treatment are essential to preventing irreversible vision loss from optic nerve damage. Delestre et al.14 performed a systematic review of 123 cases of ophthalmic disease in CLL patients and determined that 52.0% of patients had CLL-infiltration of the eye, 26.0% had eye infiltration by transformed or a second lymphoma, and 15.4% had an infectious etiology. They reported that each of these presentations generally had unique radiological and clinical characteristics. Because tissue confirmation was unavailable, this case is best interpreted as presumed optic nerve head involvement concerning for leukemic infiltration rather than pathologically proven infiltration. The differential diagnosis also included papilledema, ischemic or inflammatory optic neuropathy, diabetic papillopathy, and infectious or medication-related optic disc edema, which were considered less likely based on neuroimaging, systemic workup, and clinical course. Richter transformation with diffuse large B-cell lymphoma could not be definitively excluded without tissue diagnosis, but was considered less likely given the indolent treatment-naïve CLL course, absence of systemic features suggestive of transformation, and favorable response to BTK inhibition. CLL-infiltration can affect the optic nerve via multiple mechanisms, including direct extension, ischemia, or inflammation. The optic nerve has been described as a privileged site, relatively unaffected by systemic chemotherapy.15,16 Therefore, it might require adjunctive administration with high-dose steroids, intrathecal methotrexate, or a separate treatment modality, such as radiotherapy, for leukemic optic nerve involvement.17 There is not yet a specific treatment guideline for CNS infiltration of CLL, and the prognosis is determined by the disease characteristics.18 A wide range of treatment modalities is reported in the literature. Khan et al.19 reported a 45-year-old man with CLL and optic neuropathy, proven by optic nerve sheath biopsy, who experienced visual recovery after treatment with ibrutinib and intrathecal methotrexate. Currie et al.20 reported three cases with considerable clinical improvement after using optic nerve irradiation. Ibrutinib, lenalidomide, and venetoclax can also be effective for CNS lesions in patients with B-cell malignancy in part because they cross the blood-brain barrier (BBB) 21, 22, 23. Similarly, they could be useful in treating optic nerve infiltration in CLL patients.9 BTK is a non-redundant signaling molecule in the B-cell receptor signaling pathway, which is crucial for B-cell survival, proliferation, and function. The first approved covalent-binding BTK inhibitor (BTKi) ibrutinib considerably improved outcomes of initial and subsequent treatments for progressive CLL.24 Chauhan et al.10 reported a case of a 66-year-old male with ocular CLL who reported a significant improvement in vision 4 weeks after starting ibrutinib at a dose of 560 mg daily for retinal and choroidal CLL involvement. He continued to use it for maintenance but subsequently developed increased bruising and severe diarrhea, which are well-described complications of ibrutinib therapy.25 In contrast, second-generation BTKi, such as acalabrutinib, are more selective and associated with higher tolerability even in patients with extensive comorbidities.26 Their patient was then successfully transitioned to the second-generation BTKi acalabrutinib after initial ibrutinib therapy, which is a more selective inhibitor of BTK and has fewer off-target effects, and his vision continued to improve. The rapid resolution of symptoms observed in our case might indicate that its CNS and ocular penetration are sufficient to treat mild-to-moderate optic nerve infiltration without adjunct therapy. It remains uncertain whether the improvement reflected direct treatment of ocular involvement, systemic CLL control, or both. Although spontaneous fluctuation cannot be excluded, the prompt and sustained anatomical improvement after acalabrutinib initiation supports a treatment-associated response. Acalabrutinib has been shown to achieve adequate CNS bioavailability in preclinical studies.27 This may extend to ocular tissues due to similarities in blood-tissue barrier dynamics. Acalabrutinib can exert its anti-leukemic effect with apparent efficacy at privileged sites, such as the CNS and optic nerve head, without needing adjunct corticosteroids to bypass the BBB. No corticosteroids were administered in our case, as vision remained preserved and targeted systemic therapy was initiated promptly. Consequently, acalabrutinib can potentially be an effective monotherapy for patients with optic neuropathy infiltration, when invasive diagnostics or treatments are contraindicated or declined, such as in elderly or high-risk surgical patients. In conclusion, ophthalmologists and hematologists should be aware of the potential role of acalabrutinib in selected patients with presumed optic nerve infiltration of CLL; however, tissue diagnosis remains important when alternative pathology is suspected. Larger studies are needed to better define its role relative to established diagnostic and treatment approaches. CRediT authorship contribution statement Fatma F. Shakarchi: Writing – review & editing, Visualization, Validation, Data curation. Joseph A. Chacko: Writing – review & editing, Validation, Data curation. Joseph G. Chacko: Writing – review & editing, Validation, Formal analysis. Rangaswamy Govindarajan: Writing – review & editing, Validation, Formal analysis. Clive S. Zent: Writing – review & editing, Validation, Formal analysis. Sami H. Uwaydat: Writing – review & editing, Validation, Supervision, Formal analysis, Conceptualization. Patient consent Consent to publish this case report has been obtained from the patient in writing. Authorship All authors attest that they meet the current ICMJE criteria for Authorship. Artificial intelligence statement Artificial intelligence was not used in the preparation of this manuscript. Ethics statement The study was approved by the institutional review board of the University of Arkansas for Medical Sciences, and the patient provided consent for the study. The study followed the tenets of the Declaration of Helsinki and the Health Insurance Portability and Accountability Act. Funding No funding or grant support. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.